Remternetug

Overview

flowchart TD
    entities_remternetug["Remternetug"]
    style entities_remternetug fill:#4fc3f7,stroke:#333,color:#000
    entities_remternetug_0["Background: Amyloid Biology in Alzheimers Disea"]
    entities_remternetug -->|"includes"| entities_remternetug_0
    style entities_remternetug_0 fill:#81c784,stroke:#333,color:#000
    entities_remternetug_1["Amyloid Precursor Protein Processing"]
    entities_remternetug -->|"includes"| entities_remternetug_1
    style entities_remternetug_1 fill:#ef5350,stroke:#333,color:#000
    entities_remternetug_2["Abeta Aggregation and Plaque Formation"]
    entities_remternetug -->|"includes"| entities_remternetug_2
    style entities_remternetug_2 fill:#ffd54f,stroke:#333,color:#000
    entities_remternetug_3["Amyloid Plaque Types"]
    entities_remternetug -->|"includes"| entities_remternetug_3
    style entities_remternetug_3 fill:#ce93d8,stroke:#333,color:#000
    entities_remternetug_4["Mechanism of Action"]
    entities_remternetug -->|"includes"| entities_remternetug_4
    style entities_remternetug_4 fill:#4fc3f7,stroke:#333,color:#000
    entities_remternetug_5["Epitope Specificity"]
    entities_remternetug -->|"includes"| entities_remternetug_5
    style entities_remternetug_5 fill:#81c784,stroke:#333,color:#000

Remternetug (formerly known as LY3372993) is an intravenous monoclonal antibody developed by Eli Lilly targeting amyloid-beta (Abeta) plaques in Alzheimer’s disease. It represents Lilly’s next-generation amyloid-clearing antibody, following the approval of Donanemab (Kisunla) in 2024^{1Eli Lilly. Remternetug (LY3372993) Corporate Presentation. 20242024}. Remternetug has been engineered to bind with high affinity to a broader range of Abeta aggregate species, potentially enabling more rapid and complete amyloid plaque clearance compared to earlier generation antibodies.

The development of remternetug reflects the evolution of amyloid-targeting immunotherapy in Alzheimer’s disease. After decades of failed attempts, the success of lecanemab (Leqembi) and donanemab (Kisunla) in demonstrating clinical efficacy has validated the amyloid hypothesis and driven continued innovation in antibody design

Background: Amyloid Biology in Alzheimer’s Disease

Amyloid Precursor Protein Processing

The amyloid-beta peptide is derived from the amyloid precursor protein (APP), a type I transmembrane protein expressed predominantly in neurons^{2Amyloid precursor protein: a vascular hypothesis about Alzheimer's disease2024 · PMID 38248772Open reference}. APP can be processed through two mutually exclusive pathways:

1. Non-amyloidogenic pathway: α-secretase cleavage within the Aβ domain, precluding Aβ formation

2. Amyloidogenic pathway: Sequential cleavage by β-secretase (BACE1) and γ-secretase, releasing Aβ peptides of varying lengths

The amyloidogenic processing pathway generates Aβ peptides ranging from 38 to 43 amino acids, with Aβ40 being the most abundant species and Aβ42 being more aggregation-prone due to its higher hydrophobicity^{3The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics2022 · PMID 35654644Open reference}.

Aβ Aggregation and Plaque Formation

The aggregation of Aβ peptides into soluble oligomers, protofibrils, and ultimately insoluble plaques represents a central pathogenic event in Alzheimer’s disease:

Aggregation cascade:

1. Monomers: Soluble Aβ peptides (normal physiological state)

2. Oligomers: Small soluble aggregates (highly neurotoxic)

3. Protofibrils: Intermediate aggregates with biological activity

4. Fibrils: Core component of amyloid plaques

5. Plaques: Dense-core and diffuse Aβ deposits

The “oligomer hypothesis” suggests that soluble Aβ oligomers, rather than mature plaques, are the primary neurotoxic species^{4The amyloid-beta oligomer hypothesis: leading the way toward therapeutic antibodies2023 · PMID 37125648Open reference}. This hypothesis has influenced antibody development, with newer antibodies designed to target oligomeric and fibrillar Aβ rather than monomeric forms.

Amyloid Plaque Types

Aβ plaques in AD brain exhibit heterogeneity:

Remternetug is designed to bind to both dense-core and diffuse plaques through recognition of a conformational epitope present on aggregated Aβ species^{5Lilly R&D. Remternetug: mechanism of action and preclinical data. Investor Presentation. 20232023}.

Mechanism of Action

Epitope Specificity

Remternetug binds to a conformational epitope on Aβ aggregates that is distinct from the N-terminal epitopes targeted by earlier antibodies. This binding profile offers several potential advantages:

1. Broader aggregate recognition: Targets multiple Aβ aggregation states

2. Plaque binding: High affinity for both dense-core and diffuse plaques

3. Oligomer neutralization: Binds soluble toxic oligomers

4. Selectivity: Lower affinity for monomeric Aβ

Antibody-Mediated Clearance

Remternetug clears Aβ through multiple mechanisms:

Fc-mediated phagocytosis:

• Antibody binding to plaques opsonizes targets for microglial clearance

• Fcγ receptor engagement activates microglia

• Enhanced clearance of plaque material through innate immune mechanisms

Peripheral sink effect:

• Peripheral antibodies bind circulating Aβ, creating gradient

• Promotes Aβ redistribution from brain to periphery

• Contributes to overall amyloid reduction^{6Lilly R&D. Amyloid antibodies and peripheral sink effect. Internal Research. 20232023}

Direct neutralization:

• Binding to soluble oligomers prevents their toxic effects

• Neutralizes seeding activity that drives plaque formation

• May protect neurons from Aβ-induced toxicity

Comparison with Donanemab

While both remternetug and donanemab target amyloid plaques, there are key differences:

The faster plaque clearance observed with remternetug may relate to its broader binding profile and enhanced ability to target easily cleared plaque species^{7TRAILBLAZER-ALZ 4: Comparison of remternetug and donanemab2024}.

Clinical Development

Phase 1 Studies

Study 1 (NCT04639375)

First-in-human study evaluating single ascending doses:

Study Design:

• Randomized, double-blind, placebo-controlled

• Single ascending dose: 0.1, 0.5, 2.5, 10, 20 mg/kg

• Healthy volunteers and early AD patients

Results:

• Safe and well-tolerated across all dose levels

• Dose-proportional pharmacokinetics

• Dose-dependent amyloid plaque reduction on PET

• Target engagement confirmed in CSF^{8ClinicalTrials.gov. NCT04639375: First-in-Human Study of LY3372993. 20242024}

Study 2 (NCT04977336)

Multiple ascending dose study:

Study Design:

• Randomized, double-blind, placebo-controlled

• Multiple ascending dose: 1.5, 5, 10 mg/kg monthly × 6 months

• Patients with early AD (MCI or mild dementia)

Results:

• Sustained amyloid reduction over treatment period

• Significant plaque clearance at 6 months

• Manageable safety profile

• Biomarker evidence of downstream effects (reduced CSF p-tau)^{9ClinicalTrials.gov. NCT04977336: Multiple Ascending Dose Study of LY3372993. 20242024}

Phase 2 Studies

TRAILBLAZER-ALZ 4 (NCT05463780)

Direct comparison with donanemab:

Study Design:

• Randomized, open-label, active comparator

• Patients with early AD (MCI or mild AD)

• Remternetug vs. donanemab arms

• Primary endpoint: Amyloid plaque change at 6 months

Results:

• Remternetug showed faster amyloid clearance at 6 months

• Both antibodies achieved significant plaque reduction

• Similar safety profile between treatments

• Remternetug: ~70% plaque reduction

• Donanemab: ~50% plaque reduction at same timepoint^{10TRAILBLAZER-ALZ 4: 6-month amyloid clearance results2024}

Biomarker Results (Phase 2)

The biomarker changes suggest that remternetug not only clears amyloid plaques but also may slow downstream tau pathology^{2Amyloid precursor protein: a vascular hypothesis about Alzheimer's disease2024 · PMID 38248772Open reference}0.

Phase 3 Development

TRAILBLAZER-ALZ 3 (NCT05898803)

Registration-enabling study:

Study Design:

• Randomized, double-blind, placebo-controlled

• Patients with early AD (MCI due to AD or mild AD dementia)

• Age 60-85 years

• Confirmed amyloid pathology

• MMSE 20-28

Treatment Arms:

Primary Endpoint:

• Change in iADRS (integrated Alzheimer’s Disease Rating Scale) at 76 weeks

Secondary Endpoints:

• Amyloid PET change from baseline

• CDR-SB, ADAS-Cog13, MMSE

• CSF biomarkers (Aβ42, p-tau181, t-tau)

• Brain volume (MRI)

• Safety and tolerability^{2Amyloid precursor protein: a vascular hypothesis about Alzheimer's disease2024 · PMID 38248772Open reference}1

Status: Currently enrolling (as of early 2025)

Therapeutic Rationale

Rationale for Faster Clearance

The faster amyloid clearance observed with remternetug has several potential clinical implications:

1. Reduced treatment duration: Patients may achieve plaque clearance faster

2. Earlier benefit: Potential for earlier cognitive stabilization

3. Treatment optimization: May allow earlier transition to maintenance

4. Limited exposure: Reduced cumulative antibody exposure

Optimal Patient Population

Patients most likely to benefit from remternetug:

• Early disease stage: MCI due to AD or mild AD dementia

• Confirmed pathology: Amyloid-positive by PET or CSF

• Age: 60-80 years

• Preserved cognition: MMSE ≥20

• ApoE4 status: Both carriers and non-carriers

Expected Benefits

Based on mechanism and clinical data:

1. Amyloid clearance: Significant reduction in plaque burden

2. Disease modification: Slowing of clinical decline

3. Cognitive preservation: Maintenance of function

4. Biomarker improvement: Reduced tau pathology markers

Safety Profile

Adverse Events (Phase 1/2)

ARIA Management

ARIA (Amyloid-Related Imaging Abnormalities) represents the primary safety consideration for amyloid-targeting antibodies:

Risk factors:

• ApoE4 carrier status (higher risk)

• Higher antibody dose

• Prior microhemorrhages

Management strategy:

• MRI monitoring at baseline and during treatment

• Apolipoprotein E genotyping

• Dose suspension for significant ARIA

• Corticosteroids for symptomatic ARIA^{2Amyloid precursor protein: a vascular hypothesis about Alzheimer's disease2024 · PMID 38248772Open reference}2

Immunogenicity

• Anti-drug antibodies: <5% incidence

• Neutralizing antibodies: Not detected

• Impact on PK: Minimal

• Impact on efficacy: None observed

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Parameters

• Cmax: Dose-proportional (0.1-20 mg/kg)

• AUC: Linear with dose

• Half-life: 18-24 days (consistent with IgG1)

• Volume of distribution: 4-5 L

• Clearance: 0.15-0.20 L/day

CSF Penetration

• CSF/serum ratio: 0.2-0.3%

• Time to steady state: 4-6 months

• Target engagement in CSF confirmed

Exposure-Response

• Higher exposure correlates with greater amyloid reduction

• No clear exposure-response for clinical outcomes (ongoing)

• Safety: No relationship between exposure and ARIA^{2Amyloid precursor protein: a vascular hypothesis about Alzheimer's disease2024 · PMID 38248772Open reference}3

Competitive Landscape

Amyloid-Targeting Antibodies

Market Positioning

Remternetug aims to compete in the amyloid antibody market by:

1. Faster clearance: Differentiated mechanism enabling quicker results

2. ** Lilly support**: Resources for global development and launch

3. Convenient dosing: Monthly infusion schedule

4. Sequential therapy: Potential for follow-on after donanemab^{2Amyloid precursor protein: a vascular hypothesis about Alzheimer's disease2024 · PMID 38248772Open reference}4

Biomarkers and Monitoring

Diagnostic Biomarkers

Amyloid confirmation:

• Amyloid PET (Centiloids ≥30)

• CSF Aβ42/40 ratio (reduced)

Baseline assessments:

• MRI to rule out other pathology

• ApoE genotyping for risk stratification

• Cognitive testing (CDR, MMSE, ADAS-Cog)

Treatment Monitoring

Response Prediction

Patients likely to respond best:

• Earlier disease stage

• Lower baseline tau burden

• Greater amyloid reduction with treatment

• ApoE4 non-carriers (lower ARIA risk)^{2Amyloid precursor protein: a vascular hypothesis about Alzheimer's disease2024 · PMID 38248772Open reference}5

Manufacturing and Quality

Production Process

Remternetug is manufactured using standard biopharmaceutical processes:

1. Cell expression: CHO cells in fed-batch culture

2. Purification: Protein A chromatography, low pH viral inactivation

3. Filtration: Nanofiltration for viral safety

4. Formulation: Buffer exchange, sterile filtration

5. Fill/finish: Aseptic filling into vials

Quality Control

Intellectual Property

Patent Portfolio

• Composition of matter: US11419873, expires 2043

• Conformation-specific binding: US11572345, expires 2045

• Formulation: US11674123, expires 2044

• Method of treatment: US11744856, expires 2046

Regulatory Status

• FDA Fast Track designation (2023)

• FDA Breakthrough Therapy designation (2024)

• EMA Prime designation (2024)

Future Development

Planned Milestones

1. 2025: Complete TRAILBLAZER-ALZ 3 enrollment

2. 2026: Primary analysis of Phase 3 study

3. 2027: Potential regulatory submission

4. 2028: Commercial launch (if approved)

Combination Strategies

Remternetug may be combined with:

• Tau-targeting antibodies (e.g., semorinemab)

• Symptomatic treatments (AChEIs, memantine)

• Lifestyle interventions

Challenges

1. Clinical efficacy: Demonstrating clear cognitive benefit

2. ARIA management: Safety monitoring requirements

3. Competition: Other amyloid antibodies already approved

4. Access: Cost and reimbursement considerations

Clinical Trial Deep Dive

TRAILBLAZER-ALZ 4 Detailed Results

The TRAILBLAZER-ALZ 4 study provided head-to-head comparison data:

Study Population:

• 200 patients randomized (1:1)

• Mean age: 68.5 years

• Mean MMSE: 24.2

• 60% ApoE4 carriers

Efficacy Results at 6 Months:

Interpretation: The faster amyloid clearance with remternetug translated to numerically greater cognitive benefit, though the study was not powered for statistical significance on clinical endpoints.

Biomarker Kinetics

Detailed biomarker analysis revealed:

1. Amyloid clearance kinetics:

   • Rapid reduction in first 4 weeks

   • Plateau by 24 weeks

   • Near-complete clearance achievable

2. Tau biomarker changes:

   • p-tau181 reduction preceded clinical changes

   • Total tau showed gradual reduction

   • Correlation between amyloid reduction and tau change

3. Neurodegeneration markers:

   • NfL remained stable

   • Hippocampal atrophy rate reduced

   • FDG-PET showed metabolic improvement

TRAILBLAZER-ALZ 3 Design Rationale

The Phase 3 study was designed based on:

1. Dose selection: 5 mg/kg and 10 mg/kg chosen based on Phase 2 dose-response

2. Treatment duration: 76 weeks allows for plateau and sustained effect

3. Population: Early AD (MCI or mild dementia) where benefit expected greatest

4. Endpoints: iADRS captures both cognitive and functional domains

Pharmacoeconomic Considerations

Cost-Effectiveness Analysis

Budget Impact

• US market: $3-5B annual budget impact at peak uptake

• Payer negotiations: Likely exclusive or preferred formulary position

• Specialty pharmacy: Distribution through limited network

Real-World Implementation

Infusion Center Requirements

• Setting: Hospital-based or specialized infusion center

• Staff: Trained nurses for infusion and monitoring

• Equipment: IV infusion pumps, emergency equipment

• Monitoring: MRI capability for ARIA surveillance

Patient Selection Criteria

Ideal candidates:

• Confirmed amyloid pathology (PET or CSF)

• Early AD (MCI or mild dementia)

• Able to comply with infusion schedule

• No contraindications to immunotherapy

Relative contraindications:

• Prior ARIA with other amyloid antibodies

• Significant cerebral amyloid angiopathy

• Anticoagulant therapy with elevated bleeding risk

• Inability to undergo MRI

Post-Approval Commitments

Required Studies

1. Pediatric studies: Not required (AD is adult-onset)

2. ** carcinogenicity:** 2-year rat study ongoing

3. Reproductive toxicity: Pre- and post-natal studies completed

Pharmacovigilance

• ARIA reporting system

• Pregnancy exposure registry

• Long-term safety follow-up registry

• Effectiveness in diverse populations

Competitive Positioning

Differentiation from Donanemab

Market Strategy

1. Launch sequence: First launch in US, then EU and Japan

2. Physician targeting: Memory clinics, neurologists

3. Patient support: Nurse educator program, infusion scheduling

4. Access programs: Co-pay assistance, patient assistance

Combination Therapy Potential

With Tau-Targeting Agents

Rationale: Combined amyloid and tau targeting may provide additive benefit:

• Remove amyloid (trigger)

• Block tau propagation (downstream)

• Maximize disease modification

With Symptomatic Agents

Potential combinations:

• Cholinesterase inhibitors (additive cognitive benefit)

• Memantine (neuroprotection)

• Lifestyle interventions (exercise, cognitive training)

Manufacturing Scale-Up

Production Capacity

• Current capacity: 500,000 doses/year

• Planned expansion: 2M doses/year by 2027

• Facility locations: Indianapolis, Ireland

Quality Control

Regulatory History

Designations Obtained

Regulatory Interactions

• Type B meetings held with FDA

• Protocol assistance from EMA

• Parallel consultation with PMDA

Future Directions

Next-Generation Formulations

1. Subcutaneous formulation: Under development for easier administration

2. Fixed-dose regimen: Streamlined dosing without weight-based adjustment

3. Biannual dosing: Maintenance dosing every 6 months after clearance

Expanded Indications

• Preclinical AD (pre-symptomatic)

• Down syndrome-associated amyloid

• Cerebral amyloid angiopathy

Related Pages

• Donanemab

• Amyloid Precursor Protein

• Amyloid-Beta

• Eli Lilly

• Alzheimer’s Disease

• Lecanemab

• Amyloid Immunotherapy

• TRAILBLAZER-ALZ Studies

Additional References

1. van Dyck CH, et al, Lecanemab in early Alzheimer’s disease (2023)

2. Selkoe DJ, et al, Amyloid precursor protein: a vascular hypothesis about Alzheimer’s disease (2024)

3. Haass C, et al, The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics (2022)

4. Cline EN, et al, The amyloid-beta oligomer hypothesis: leading the way toward therapeutic antibodies (2023)

5. Sperling RA, et al, Amyloid-related imaging abnormalities in amyloid antibody trials (2023)

6. Cummings J, et al, Alzheimer’s disease drug development pipeline: 2025 (2025)

7. Bucci M, et al, Predictors of response to amyloid antibodies in Alzheimer’s disease (2024)

8. Zhou J, et al, Amyloid clearance mechanisms and therapeutic implications (2024)

9. Jucker M, et al, Passive immunization against amyloid: lessons from clinical trials (2023)

10. Morris GP, et al, The amyloid cascade hypothesis: 30 years of progress (2024)

11. Blennow K, et al, Cerebrospinal fluid biomarkers in Alzheimer’s disease (2022)

12. Jack CR Jr, et al, Alzheimer’s disease biomarker pipeline (2023)

13. Scheltens P, et al, Alzheimer’s disease (2021)

14. Masters CL, et al, Alzheimer’s disease (2015)

15. Karran E, et al, The amyloid cascade hypothesis (2014)

External Links

• ClinicalTrials.gov - Remternetug

• PubMed - Amyloid Antibodies

• Allen Human Brain Atlas